Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperlipidemia and Mixed Dyslipidemia Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

NCT07592858
View directory record Official record
Conditions
PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky • Augusta, Maine
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
View directory record Official record
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT02944383
View directory record Official record
Conditions
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
Interventions
Gemcabene, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 4 Interventional

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

NCT00345657
View directory record Official record
Conditions
Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
Interventions
Niacin Extended Release/Lovastatin
Drug
Lead sponsor
In His Image
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

NCT02458287
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Jul 23, 2026, 6:30 PM EDT
Terminated Phase 3 Interventional

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

NCT00134238
View directory record Official record
Conditions
Mixed Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

NCT01849497
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

NCT02662569
View directory record Official record
Conditions
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab, Atorvastatin, Placebo
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jul 23, 2026, 6:30 PM EDT
Completed No phase listed Observational

A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients

NCT07409636
View directory record Official record
Conditions
Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 6:30 PM EDT
Active, not recruiting Not applicable Interventional

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

NCT05088759
View directory record Official record
Conditions
Hyperlipemia, Mixed, ASCVD
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 4 Interventional

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039
View directory record Official record
Conditions
Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions
colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
30 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

NCT00465088
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Niacin ER/Simvastatin Tablets, atorvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2011 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

NCT04516291
View directory record Official record
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions
Vupanorsen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
59
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mixed Meal Challenge Study

NCT05087823
View directory record Official record
Conditions
Cardiovascular Diseases, Hyperlipidemias
Interventions
Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 1 Interventional Results available

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

NCT02275156
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 23, 2026, 6:30 PM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

NCT02670434
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
NK-104-CR, Placebo, Livalo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
45
States / cities
Beverly Hills, California • Chino, California • Lincoln, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 23, 2026, 6:30 PM EDT
Recruiting Phase 1 Interventional

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172
View directory record Official record
Conditions
Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions
CTX310
Drug
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 6:30 PM EDT
Recruiting Not applicable Interventional

Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial

NCT07119658
View directory record Official record
Conditions
Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome, Obesity &Amp; Overweight, Diabetes, Hyperlipidemia, Emergency Medicine
Interventions
Composite intervention to address MetS
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

NCT01854918
View directory record Official record
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Interventions
Evolocumab, Standard of Care
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
107
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 23, 2026, 6:30 PM EDT
Withdrawn Not applicable Interventional

Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART

NCT00572429
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia, Exercise
Interventions
l-carnitine
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Jul 23, 2026, 6:30 PM EDT